Atazanavir (BioDeep_00000397565)
代谢物信息卡片
methyl N-[(1S)-1-{N-[(2S,3S)-2-hydroxy-3-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanamido]-4-phenylbutyl]-N-{[4-(pyridin-2-yl)phenyl]methyl}hydrazinecarbonyl}-2,2-dimethylpropyl]carbamate
化学式: C38H52N6O7 (704.3897282)
中文名称: 阿扎那韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC
InChI: InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
CONFIDENCE standard compound; INTERNAL_ID 2148
CONFIDENCE standard compound; EAWAG_UCHEM_ID 3012
同义名列表
数据库引用编号
40 个数据库交叉引用编号
- ChEBI: CHEBI:37924
- KEGGdrug: D07471
- PubChem: 148192
- Metlin: METLIN85464
- DrugBank: DB01072
- ChEMBL: CHEMBL1163
- MeSH: Atazanavir Sulfate
- CAS: 198904-31-3
- MoNA: AU214834
- MoNA: AU214833
- MoNA: AU214832
- MoNA: AU214831
- MoNA: AU214811
- MoNA: AU214810
- MoNA: AU214809
- MoNA: AU214808
- MoNA: AU214807
- MoNA: EQ301256
- MoNA: EQ301255
- MoNA: EQ301254
- MoNA: EQ301253
- MoNA: EQ301252
- MoNA: EQ301251
- MoNA: EQ301206
- MoNA: EQ301205
- MoNA: EQ301204
- MoNA: EQ301203
- MoNA: EQ301202
- MoNA: EQ301201
- MoNA: AU214855
- MoNA: AU214854
- MoNA: AU214853
- MoNA: AU214852
- MoNA: AU214851
- MoNA: AU214805
- MoNA: AU214804
- MoNA: AU214803
- MoNA: AU214802
- MoNA: AU214801
- RefMet: Atazanavir
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Smritilekha Mondal, Arvind Sirvi, Karan Jadhav, Abhay T Sangamwar. Supersaturating lipid-based solid dispersion of atazanavir provides enhanced solubilization and supersaturation in the digestive aqueous phase.
International journal of pharmaceutics.
2023 May; 638(?):122919. doi:
10.1016/j.ijpharm.2023.122919. [PMID: 37011828] - José L Blanco, Jhon Rojas, Elisa de Lazzari, Alexy Inciarte, Mar Subirana, Pilar Callau, María Martinez-Rebollar, Montserrat Laguno, Josep Mallolas, Lorena de la Mora, Berta Torres, Ana Gonzalez-Cordón, Esteban Martinez. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
The Journal of antimicrobial chemotherapy.
2022 06; 77(7):1974-1979. doi:
10.1093/jac/dkac137. [PMID: 35512339] - Vishal C Gurumukhi, Sanjaykumar B Bari. Quality by design (QbD)-based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies.
Drug delivery and translational research.
2022 05; 12(5):1230-1252. doi:
10.1007/s13346-021-01014-4. [PMID: 34110597] - Maiara Camotti Montanha, Francesc Fabrega, Alice Howarth, Nicolas Cottura, Hannah Kinvig, Fazila Bunglawala, Andrew Lloyd, Paolo Denti, Catriona Waitt, Marco Siccardi. Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling.
Clinical pharmacokinetics.
2022 03; 61(3):375-386. doi:
10.1007/s40262-021-01067-1. [PMID: 34635995] - Jeremiah D Momper, Jiajia Wang, Alice Stek, David E Shapiro, Kathleen M Powis, Mary E Paul, Martina L Badell, Renee Browning, Nahida Chakhtoura, Kayla Denson, Kittipong Rungruengthanakit, Kathleen George, Edmund V Capparelli, Mark Mirochnick, Brookie M Best. Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.
Journal of acquired immune deficiency syndromes (1999).
2022 03; 89(3):303-309. doi:
10.1097/qai.0000000000002856. [PMID: 34732682] - Hossein Mazaherpour, Masoomeh Sofian, Elham Farahani, Alireza Abdi, Sakine Mazaherpour, Anahita Bavand, Amitis Ramezani. Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
BioMed research international.
2022; 2022(?):1522426. doi:
10.1155/2022/1522426. [PMID: 35013710] - Wondmagegn Tamiru Tadesse, Birhanemeskel T Adankie, Workineh Shibeshi, Wondwossen Amogne, Eleni Aklillu, Ephrem Engidawork. Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.
PloS one.
2022; 17(1):e0262604. doi:
10.1371/journal.pone.0262604. [PMID: 35045105] - Israel Silva Maia, Aline Marcadenti, Fernando Godinho Zampieri, Lucas Petri Damiani, Renato Hideo Nakagawa Santos, Karina Leal Negrelli, Samara Pinheiro do Carmo Gomes, Jaqueline Oliveira Gomes, Mariana Barbosa Dos Santos Carollo, Tamiris Abait Miranda, Eliana Santucci, Nanci Valeis, Ligia Nasi Laranjeira, Glauco Adrieno Westphal, Jacques Gabriel Alvares Horta, Uri Adrian Prync Flato, Camilo Fernandes, Waldemar Carlos Barros, Renata S Bolan, Otávio Celso Eluf Gebara, Meton Soares de Alencar Filho, Victor Augusto Hamamoto, Mauro Esteves Hernandes, Nicole Alberti Golin, Ronald Torres de Olinda, Flávia Ribeiro Machado, Régis Goulart Rosa, Viviane Cordeiro Veiga, Luciano César Pontes de Azevedo, Alvaro Avezum, Renato Delascio Lopes, Tiago Moreno L Souza, Otávio Berwanger, Alexandre Biasi Cavalcanti. Antivirals for adult patients hospitalized with SARS-CoV-2 infection: A randomized, Phase II/III, multicenter, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX - REVOLUTIOn: protocol and statistical analysis plan.
Revista Brasileira de terapia intensiva.
2022 Jan; 34(1):44-55. doi:
10.5935/0103-507x.20220002-pt. [PMID: 35766657] - Regis Kreitchmann, Alice Stek, Brookie M Best, Edmund Capparelli, JiaJia Wang, David Shapiro, Nahida Chakhtoura, Mark Mirochnick, Ahizechukwu C Eke. Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.
Contraception.
2022 01; 105(?):67-74. doi:
10.1016/j.contraception.2021.08.006. [PMID: 34407424] - Saeed Kalantari, Soheil R Fard, Donya Maleki, Mahshid T Taher, Zeynab Yassin, Yousef Alimohamadi, Sara Minaeian. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Journal of medical virology.
2021 12; 93(12):6557-6565. doi:
10.1002/jmv.27195. [PMID: 34255369] - Shahram Seyfi, Kayvan Latifi, Parviz Amri Male, Mahmoud Sadeghi Haddad Zavareh, Khadijeh Ezoji, Mousa Mohammadnia-Afrozi. Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients.
International immunopharmacology.
2021 Dec; 101(Pt B):108241. doi:
10.1016/j.intimp.2021.108241. [PMID: 34688151] - Stephen I Walimbwa, Julian P Kaboggoza, Catriona Waitt, Pauline Byakika-Kibwika, Antonio D'Avolio, Mohammed Lamorde. An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Trials.
2021 Nov; 22(1):831. doi:
10.1186/s13063-021-05752-1. [PMID: 34814933] - Abdullahi Tsanni. African scientists race to test COVID drugs - but face major hurdles.
Nature.
2021 11; 599(7883):25-27. doi:
10.1038/d41586-021-02995-5. [PMID: 34732862] - Camilla Ingrid Hatleberg, Lene Ryom, Caroline Sabin. Cardiovascular risks associated with protease inhibitors for the treatment of HIV.
Expert opinion on drug safety.
2021 Nov; 20(11):1351-1366. doi:
10.1080/14740338.2021.1935863. [PMID: 34047238] - Sikiru Olatunji Usman, Ibrahim Adekunle Oreagba, Michael Rotimi Kadri, Ololade Oluwatosin Adewumi, Akinwumi Akinyede, Esther Oluwatoyin Agbaje, Ganiyu Abideen, AbdulWasiu Adeniyi Busari, Olayinka Olaiwola Hassan, Moshood Olusola Akinleye, Alani Sulaimon Akanmu. Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria.
European journal of clinical pharmacology.
2021 Sep; 77(9):1341-1348. doi:
10.1007/s00228-021-03116-x. [PMID: 33755736] - Yuhang Wang, Sruthi Murlidaran, David A Pearlman. Quantum simulations of SARS-CoV-2 main protease Mpro enable high-quality scoring of diverse ligands.
Journal of computer-aided molecular design.
2021 09; 35(9):963-971. doi:
10.1007/s10822-021-00412-7. [PMID: 34328586] - Denio A Ridjab, Ignatius Ivan, Fanny Budiman, Dwi Jani Juliawati. Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review.
Medicine.
2021 Aug; 100(31):e26787. doi:
10.1097/md.0000000000026787. [PMID: 34397829] - Ninad S Chaudhary, Tobias Kind, Amanda L Willig, Michael S Saag, Sadeep Shrestha, Nicholas Funderburg, Howard W Wiener, E Turner Overton, Marguerite R Irvin. Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.
Medicine.
2021 Jul; 100(30):e26588. doi:
10.1097/md.0000000000026588. [PMID: 34397689] - R N Dallocchio, A Dessì, A De Vito, G Delogu, P A Serra, G Madeddu. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?.
European review for medical and pharmacological sciences.
2021 Mar; 25(5):2435-2448. doi:
10.26355/eurrev_202103_25285. [PMID: 33755983] - Dorina van der Mey, Michael Gerisch, Natalia A Jungmann, Andreas Kaiser, Kenichi Yoshikawa, Simone Schulz, Martin Radtke, Silvia Lentini. Drug-drug interaction of atazanavir on UGT1A1-mediated glucuronidation of molidustat in human.
Basic & clinical pharmacology & toxicology.
2021 Mar; 128(3):511-524. doi:
10.1111/bcpt.13538. [PMID: 33232579] - Fadhel A Alomar, Chengju Tian, Prasanta K Dash, JoEllyn M McMillan, Howard E Gendelman, Santhi Gorantla, Keshore R Bidasee. Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca2+ homeostasis in skeletal muscles.
Antiviral research.
2021 03; 187(?):104975. doi:
10.1016/j.antiviral.2020.104975. [PMID: 33450312] - Chunlong Ma, Jun Wang. Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America.
2021 02; 118(8):. doi:
10.1073/pnas.2024420118. [PMID: 33568498] - Zhe Li, Yuxi Lin, Yi-You Huang, Runduo Liu, Chang-Guo Zhan, Xin Wang, Hai-Bin Luo. Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America.
2021 02; 118(8):. doi:
10.1073/pnas.2024937118. [PMID: 33568500] - Sadanori Akita, Keiji Suzuki, Hiroshi Yoshimoto, Akira Ohtsuru, Akiyoshi Hirano, Shunichi Yamashita. Cellular Mechanism Underlying Highly-Active or Antiretroviral Therapy-Induced Lipodystrophy: Atazanavir, a Protease Inhibitor, Compromises Adipogenic Conversion of Adipose-Derived Stem/Progenitor Cells through Accelerating ER Stress-Mediated Cell Death in Differentiating Adipocytes.
International journal of molecular sciences.
2021 Feb; 22(4):. doi:
10.3390/ijms22042114. [PMID: 33672735] - Adeniyi Olagunju, Adeola Fowotade, Ajibola Olagunoye, Temitope Olumuyiwa Ojo, Bolanle Olufunlola Adefuye, Adeniyi Francis Fagbamigbe, Akindele Olupelumi Adebiyi, Omobolanle Ibitayo Olagunju, Olabode Taiwo Ladipo, Abdulafeez Akinloye, Babatunde Ayodeji Adeagbo, Adedeji Onayade, Oluseye Oladotun Bolaji, Christian Happi, Steve Rannard, Andrew Owen. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Trials.
2021 Jan; 22(1):3. doi:
10.1186/s13063-020-04987-8. [PMID: 33397457] - Fernando Geldres-Molina, Alex Castañeda-Sabogal, Maryori M Hilario-Gómez, Joshuan J Barboza. Lipid profile levels in HIV-AIDS patients on treatment with efavirenz and atazanavir. Cohort study.
Gaceta medica de Mexico.
2021; 157(4):384-390. doi:
10.24875/gmm.m21000579. [PMID: 35133341] - Masoud Mardani, Athena Sharifi-Razavi, Shirin Sheibani, Mana Baziboroun. Outcome of a HIV Positive Patient Infected with COVID-19 After an Autologous Bone Marrow Transplantation: A Case Report.
Current HIV research.
2021; 19(4):377-382. doi:
10.2174/1570162x19666210423124839. [PMID: 33902413] - Erika Tyrberg, Arvid Edén, Jaran Eriksen, Staffan Nilsson, Carl Johan Treutiger, Anders Thalme, Åsa Mellgren, Magnus Gisslén, Lars-Magnus Andersson. Higher plasma drug levels in elderly people living with HIV treated with darunavir.
PloS one.
2021; 16(2):e0246171. doi:
10.1371/journal.pone.0246171. [PMID: 33539440] - İrfan Aygün, Mehmet Kaya, Reda Alhajj. Identifying side effects of commonly used drugs in the treatment of Covid 19.
Scientific reports.
2020 12; 10(1):21508. doi:
10.1038/s41598-020-78697-1. [PMID: 33299085] - Murugaiah A M Subbaiah, Thangeswaran Ramar, Lakshumanan Subramani, Salil D Desai, Sarmistha Sinha, Sandhya Mandlekar, Susan M Jenkins, Mark R Krystal, Murali Subramanian, Srikanth Sridhar, Shweta Padmanabhan, Priyadeep Bhutani, Rambabu Arla, John F Kadow, Nicholas A Meanwell. (Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration.
European journal of medicinal chemistry.
2020 Dec; 207(?):112749. doi:
10.1016/j.ejmech.2020.112749. [PMID: 33065417] - Hamid Rahmani, Effat Davoudi-Monfared, Anahid Nourian, Morteza Nabiee, Setayesh Sadeghi, Hossein Khalili, Ladan Abbasian, Fereshteh Ghiasvand, Arash Seifi, Malihe Hasannezhad, Sara Ghaderkhani, Mostafa Mohammadi, Mir Saeed Yekaninejad. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences.
2020 Dec; 28(2):625-634. doi:
10.1007/s40199-020-00369-2. [PMID: 32857301] - Michael Li, Walter W Chan, Stephen D Zucker. Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
Journal of the American Heart Association.
2020 10; 9(19):e016310. doi:
10.1161/jaha.120.016310. [PMID: 32930032] - Natalia Fintelman-Rodrigues, Carolina Q Sacramento, Carlyle Ribeiro Lima, Franklin Souza da Silva, André C Ferreira, Mayara Mattos, Caroline S de Freitas, Vinicius Cardoso Soares, Suelen da Silva Gomes Dias, Jairo R Temerozo, Milene D Miranda, Aline R Matos, Fernando A Bozza, Nicolas Carels, Carlos Roberto Alves, Marilda M Siqueira, Patrícia T Bozza, Thiago Moreno L Souza. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Antimicrobial agents and chemotherapy.
2020 09; 64(10):. doi:
10.1128/aac.00825-20. [PMID: 32759267] - Effat Davoudi-Monfared, Hamid Rahmani, Hossein Khalili, Mahboubeh Hajiabdolbaghi, Mohamadreza Salehi, Ladan Abbasian, Hossein Kazemzadeh, Mir Saeed Yekaninejad. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Antimicrobial agents and chemotherapy.
2020 08; 64(9):. doi:
10.1128/aac.01061-20. [PMID: 32661006] - Bernard Ngara, Simbarashe Zvada, Tariro Dianah Chawana, Babill Stray-Pedersen, Charles Fungai Brian Nhachi, Simbarashe Rusakaniko. A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents.
BMC pharmacology & toxicology.
2020 08; 21(1):58. doi:
10.1186/s40360-020-00437-y. [PMID: 32746923] - Hale Afshar, Zeynab Yassin, Saeed Kalantari, Oldooz Aloosh, Tayebeh Lotfi, Mehdi Moghaddasi, Alireza Sadeghipour, Maziar Emamikhah. Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical - Paraclinical follow up study of a case.
Multiple sclerosis and related disorders.
2020 Aug; 43(?):102216. doi:
10.1016/j.msard.2020.102216. [PMID: 32464585] - Elaine F Enright, Susan A Joyce, Cormac G M Gahan, Lynne S Taylor. Impact of phospholipid digests and bile acid pool variations on the crystallization of atazanavir from supersaturated solutions.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2020 Aug; 153(?):68-83. doi:
10.1016/j.ejpb.2020.05.022. [PMID: 32473291] - Oguzhan Fırat, Nadir Yalçın, Kutay Demirkan. COVID-19 & antiepileptic drugs: Should we pay attention?.
Seizure.
2020 08; 80(?):240-241. doi:
10.1016/j.seizure.2020.07.005. [PMID: 32663783] - Sulggi A Lee, Sushama Telwatte, Hiroyu Hatano, Angela D M Kashuba, Mackenzie L Cottrell, Rebecca Hoh, Teri J Liegler, Sophie Stephenson, Ma Somsouk, Peter W Hunt, Steven G Deeks, Steven Yukl, Radojka M Savic. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
Journal of acquired immune deficiency syndromes (1999).
2020 04; 83(5):530-537. doi:
10.1097/qai.0000000000002287. [PMID: 32168200] - David W Haas, Yoninah S Cramer, Catherine Godfrey, Susan L Rosenkranz, Francesca Aweeka, Baiba Berzins, Robert Coombs, Kristine Coughlin, Laura E Moran, David Gingrich, Carmen D Zorrilla, Paxton Baker, Susan E Cohn, Kimberly K Scarsi. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
Pharmacogenetics and genomics.
2020 04; 30(3):45-53. doi:
10.1097/fpc.0000000000000396. [PMID: 32106141] - Bereket Molla Tigabu, Feleke Doyore Agide, Minoo Mohraz, Shekoufeh Nikfar. Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.
African health sciences.
2020 Mar; 20(1):91-101. doi:
10.4314/ahs.v20i1.14. [PMID: 33402897] - Érica Lofrano Reghine, Renato Demarchi Foresto, Gianna Mastroianni Kirsztajn. HIV-related nephropathy: new aspects of an old paradigm.
Revista da Associacao Medica Brasileira (1992).
2020 Jan; 66Suppl 1(Suppl 1):s75-s81. doi:
10.1590/1806-9282.66.s1.75. [PMID: 31939539] - Kimberly K Scarsi, Yoninah S Cramer, Susan L Rosenkranz, Francesca Aweeka, Baiba Berzins, Robert W Coombs, Kristine Coughlin, Laura E Moran, Carmen D Zorrilla, Victor Akelo, Mariam Aziz, Ruth K Friedman, David Gingrich, Shobha Swaminathan, Catherine Godfrey, Susan E Cohn. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
The lancet. HIV.
2019 09; 6(9):e601-e612. doi:
10.1016/s2352-3018(19)30155-9. [PMID: 31498109] - Heidi M Crane, Robin M Nance, Susan R Heckbert, Corey Ritchings, Lisa Rosenblatt, Matthew Budoff, Brian R Wood, David L Tirschwell, H Nina Kim, William C Mathews, Elvin Geng, Richard D Moore, Peter W Hunt, Joseph J Eron, Greer A Burkholder, Daniel R Drozd, Felicia C Chow, Kyra J Becker, Joseph R Zunt, Emily L Ho, Rizwan Kalani, Andrew Huffer, Bridget M Whitney, Michael S Saag, Mari M Kitahata, Joseph A C Delaney. Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.
Journal of acquired immune deficiency syndromes (1999).
2019 08; 81(5):e141-e147. doi:
10.1097/qai.0000000000002071. [PMID: 31135582] - Noppaket Singkham, Anchalee Avihingsanon, Narukjaporn Thammajaruk, Kiat Ruxrungtham, Torsak Bunupuradah, Sasisopin Kiertiburanakul, Ploenchan Chetchotisakd, David M Burger, Sean Emery, Baralee Punyawudho. Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients.
Pharmacogenomics.
2019 05; 20(7):517-527. doi:
10.2217/pgs-2018-0196. [PMID: 31124411] - Murugaiah A M Subbaiah, Sandhya Mandlekar, Sridhar Desikan, Thangeswaran Ramar, Lakshumanan Subramani, Mathiazhagan Annadurai, Salil D Desai, Sarmistha Sinha, Susan M Jenkins, Mark R Krystal, Murali Subramanian, Srikanth Sridhar, Shweta Padmanabhan, Priyadeep Bhutani, Rambabu Arla, Shashyendra Singh, Jaydeep Sinha, Megha Thakur, John F Kadow, Nicholas A Meanwell. Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir.
Journal of medicinal chemistry.
2019 04; 62(7):3553-3574. doi:
10.1021/acs.jmedchem.9b00002. [PMID: 30938524] - Bartłomiej Matłosz, Ewa Pietraszkiewicz, Ewa Firląg-Burkacka, Ewa Grycner, Andrzej Horban, Justyna D Kowalska. Risk factors for kidney disease among HIV-1 positive persons in the methadone program.
Clinical and experimental nephrology.
2019 Mar; 23(3):342-348. doi:
10.1007/s10157-018-1644-5. [PMID: 30218298] - Alberto Borghetti, Francesca Lombardi, Roberta Gagliardini, Gianmaria Baldin, Arturo Ciccullo, Davide Moschese, Arianna Emiliozzi, Simone Belmonti, Silvia Lamonica, Francesca Montagnani, Elena Visconti, Andrea De Luca, Simona Di Giambenedetto. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
BMC infectious diseases.
2019 Jan; 19(1):59. doi:
10.1186/s12879-018-3666-8. [PMID: 30654739] - Sophia R Majeed, Steve West, Kah Hiing Ling, Moupali Das, Brian P Kearney. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Antiviral therapy.
2019; 24(8):557-566. doi:
10.3851/imp3343. [PMID: 31933482] - Geetha Ramachandran, A K Hemanth Kumar, T Kannan, R Sridhar, S K Guha, Deelip Kadam, N Poorana Gangadevi, T Rajapandian. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients.
The Indian journal of tuberculosis.
2019 Jan; 66(1):129-133. doi:
10.1016/j.ijtb.2018.06.009. [PMID: 30797270] - Miantezila B Joe, Landman Roland, Chouchana Laurent, Lê M Patrick, Olivier Sawoo, Tona L Gaston, Eto Bruno, Peytavin Gilles, Pochart Philippe. Concomitant Use of Cotrimoxazole and Atazanavir in HIV-infected Patients: A Therapeutic Drug Monitoring and Pharmacovigilance Based Dual Approach.
Current clinical pharmacology.
2019; 14(3):214-223. doi:
10.2174/1574884714666190405160612. [PMID: 30961507] - Joe Miantezila Basilua, Olivier Sawoo, Irène Mangin, Flore Dossou-Yovo, Aline Boussard, Lucie Chevillard, Gaston T Lutete, Bruno Eto, Gilles Peytavin, Philippe Pochart. Higher Atazanavir Plasma Exposure in Rats is Associated with Gut Microbiota Changes Induced by Cotrimoxazole.
Current drug metabolism.
2019; 20(11):898-906. doi:
10.2174/1389200220666191023105609. [PMID: 31702484] - Lama ElZohary, William B Weglicki, Joanna J Chmielinska, Jay H Kramer, I Tong Mak. Mg-supplementation attenuated lipogenic and oxidative/nitrosative gene expression caused by Combination Antiretroviral Therapy (cART) in HIV-1-transgenic rats.
PloS one.
2019; 14(1):e0210107. doi:
10.1371/journal.pone.0210107. [PMID: 30668566] - Esther Muya, Appolinary Kamuhabwa. Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs.
Journal of the International Association of Providers of AIDS Care.
2019 Jan; 18(?):2325958219841908. doi:
10.1177/2325958219841908. [PMID: 30995874] - Simone Perazzolo, Laura M Shireman, Josefin Koehn, Lisa A McConnachie, John C Kraft, Danny D Shen, Rodney J Y Ho. Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
Journal of pharmaceutical sciences.
2018 12; 107(12):3153-3162. doi:
10.1016/j.xphs.2018.07.032. [PMID: 30121315] - Bani Tamraz, Yong Huang, Audrey L French, Seble Kassaye, Kathryn Anastos, Marek J Nowicki, Stephen Gange, Deborah R Gustafson, Peter Bacchetti, Ruth M Greenblatt, Pirro G Hysi, Bradley E Aouizerat. A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair.
Clinical pharmacology and therapeutics.
2018 11; 104(5):949-956. doi:
10.1002/cpt.1014. [PMID: 29315502] - Nicola Squillace, Daria Trabattoni, Antonio Muscatello, Francesca Sabbatini, Alessandro Maloberti, Cristina Giannattasio, Michela Masetti, Claudio Fenizia, Alessandro Soria, Mario Clerici, Andrea Gori, Alessandra Bandera. Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
The Journal of antimicrobial chemotherapy.
2018 08; 73(8):2162-2170. doi:
10.1093/jac/dky178. [PMID: 29897513] - Arkaitz Imaz, Jordi Niubó, Alieu Amara, Saye Khoo, Elena Ferrer, Juan M Tiraboschi, Laura Acerete, Benito Garcia, Antonia Vila, Daniel Podzamczer. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39).
Journal of neurovirology.
2018 08; 24(4):391-397. doi:
10.1007/s13365-018-0626-4. [PMID: 29542028] - Lukas Cerveny, Zuzana Ptackova, Marketa Durisova, Frantisek Staud. Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats.
Reproductive toxicology (Elmsford, N.Y.).
2018 08; 79(?):57-65. doi:
10.1016/j.reprotox.2018.05.008. [PMID: 29859254] - Chiara Dentone, Antonio Di Biagio, Alessandro Cozzi Lepri, Daniela Fenoglio, Gilberto Filaci, Miriam Lichtner, Stefania Carrara, Andrea Giacometti, Laura Sighinolfi, Giulia Marchetti, Andrea Antinori, Antonella D'arminio Monforte. Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
HIV clinical trials.
2018 08; 19(4):158-162. doi:
10.1080/15284336.2018.1488453. [PMID: 30422095] - Simone Belmonti, Francesca Lombardi, Eugenia Quiros-Roldan, Alessandra Latini, Antonella Castagna, Alberto Borghetti, Gianmaria Baldin, Arturo Ciccullo, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
The Journal of antimicrobial chemotherapy.
2018 07; 73(7):1949-1954. doi:
10.1093/jac/dky125. [PMID: 29788156] - Daniele Luísa Ribeiro Alvarenga, Amanda Helen Dos Santos Silva, Jacqueline Araújo Fiuza, Soraya Torres Gaze, Jaquelline Germano de Oliveira, Rodrigo Corrêa Oliveira, Carlos Eduardo Calzavara-Silva, Marcelo Antônio Pascoal-Xavier, Érica Alessandra Rocha Alves. HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis.
International immunopharmacology.
2018 Jul; 60(?):179-188. doi:
10.1016/j.intimp.2018.04.044. [PMID: 29747123] - Emanuele Focà, Andrea Calcagno, Andrea Bonito, Jessica Cusato, Elisabetta Domenighini, Antonio D'Avolio, Eugenia Quiros Roldan, Laura Trentini, Filippo Castelnuovo, Giovanni Di Perri, Francesco Castelli, Stefano Bonora. Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir.
Antimicrobial agents and chemotherapy.
2018 07; 62(7):. doi:
10.1128/aac.00309-18. [PMID: 29760129] - Lene Ryom, Jens D Lundgren, Wafaa El-Sadr, Peter Reiss, Ole Kirk, Matthew Law, Andrew Phillips, Rainer Weber, Eric Fontas, Antonella d' Arminio Monforte, Stéphane De Wit, Francois Dabis, Camilla I Hatleberg, Caroline Sabin, Amanda Mocroft. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
The lancet. HIV.
2018 06; 5(6):e291-e300. doi:
10.1016/s2352-3018(18)30043-2. [PMID: 29731407] - Célia Lloret-Linares, Yasmin Rahmoun, Amanda Lopes, Dorothée Chopin, Guy Simoneau, Andrew Green, Brigitte Delhotal, Hélène Sauvageon, Stéphane Mouly, Jean-François Bergmann, Pierre-Olivier Sellier. Effect of body weight and composition on efavirenz, atazanavir or darunavir concentration.
Therapie.
2018 May; 73(3):185-191. doi:
10.1016/j.therap.2017.08.007. [PMID: 29395300] - M Floridia, G Masuelli, M Ravizza, B Tassis, I Cetin, M Sansone, A Degli Antoni, G Simonazzi, A Maccabruni, D Francisci, V Frisina, G Liuzzi, S Dalzero, E Tamburrini. Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study.
The Journal of antimicrobial chemotherapy.
2018 04; 73(4):1025-1030. doi:
10.1093/jac/dkx478. [PMID: 29244115] - Elisa Colella, Dario Cattaneo, Laura Galli, Sara Baldelli, Emilio Clementi, Massimo Galli, Adriano Lazzarin, Antonella Castagna, Stefano Rusconi, Vincenzo Spagnuolo. Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.
The new microbiologica.
2018 Apr; 41(2):106-111. doi:
NULL. [PMID: 29498742] - J Jao, W Yu, K Patel, T L Miller, B Karalius, M E Geffner, L A DiMeglio, A Mirza, J S Chen, M Silio, E J McFarland, R B Van Dyke, D Jacobson. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
HIV medicine.
2018 03; 19(3):175-183. doi:
10.1111/hiv.12566. [PMID: 29159965] - Jens Lundgren, Amanda Mocroft, Lene Ryom. Contemporary protease inhibitors and cardiovascular risk.
Current opinion in infectious diseases.
2018 02; 31(1):8-13. doi:
10.1097/qco.0000000000000425. [PMID: 29232276] - Akarin Hiransuthikul, Narukjaporn Thammajaruk, Isariya Techatanawat, Busarat Karachot, Bancha Chuasuwan, Chutima Manamuti, Mariam Duereh, Mathus Sawpitiporn, Jiratchaya Sophonphan, Sivaporn Gatechompol, Anchalee Avihingsanon, Chureeratana Bowonwattanuwong, Kiat Ruxrungtham. Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
Antiviral therapy.
2018; 23(8):699-703. doi:
10.3851/imp3267. [PMID: 30265243] - Alicia Gutierrez-Valencia, Coral García, Pompeyo Viciana, Yusnelkis Milanés-Guisado, Tamara Fernandez-Magdaleno, Nuria Espinosa, Juan Pasquau, Luis Fernando López-Cortés. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
PloS one.
2018; 13(9):e0203452. doi:
10.1371/journal.pone.0203452. [PMID: 30235244] - Paul Leger, Sanika Chirwa, Jacinta N Nwogu, Megan Turner, Danielle M Richardson, Paxton Baker, Michael Leonard, Husamettin Erdem, Lana Olson, David W Haas. Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.
Pharmacogenetics and genomics.
2018 Jan; 28(1):1-6. doi:
10.1097/fpc.0000000000000316. [PMID: 29117017] - Charles S Venuto, Jihoon Lim, Susan Messing, Peter W Hunt, Grace A McComsey, Gene D Morse. Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
Antiviral therapy.
2018; 23(4):345-351. doi:
10.3851/imp3209. [PMID: 29171837] - Adrienne Carmel Muller, Murray P Ducharme, Isadore Kanfer. Identification of Mechanism and Pathway of the Interaction between the African Traditional Medicine, Sutherlandia Frutescens, and the Antiretroviral Protease Inhibitor, Atazanavir, in Human Subjects Using Population Pharmacokinetic (PK) Analysis.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
2018; 21(1s):215s-221s. doi:
10.18433/jpps30068. [PMID: 30158052] - Mao-Song Tsai, Sui-Yuan Chang, Shu-Wen Lin, Ching-Hua Kuo, Hsin-Yun Sun, Bin-Ru Wu, Sue-Yo Tang, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung, Shan-Chwen Chang. Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
2017 Dec; 50(6):789-797. doi:
10.1016/j.jmii.2015.12.012. [PMID: 26857335] - Emanuele Focà, Andrea Calcagno, Andrea Bonito, Marco Simiele, Elisabetta Domenighini, Antonio D'Avolio, Eugenia Quiros Roldan, Laura Trentini, Salvatore Casari, Giovanni Di Perri, Francesco Castelli, Stefano Bonora. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
The Journal of antimicrobial chemotherapy.
2017 Nov; 72(11):3163-3166. doi:
10.1093/jac/dkx274. [PMID: 28961777] - Dominick Santoriello, Majdi Al-Nabulsi, Aravinda Reddy, Julius Salamera, Vivette D D'Agati, Glen S Markowitz. Atazanavir-Associated Crystalline Nephropathy.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2017 Oct; 70(4):576-580. doi:
10.1053/j.ajkd.2017.02.376. [PMID: 28579422] - D Metsu, P L Toutain, E Chatelut, P Delobel, P Gandia. Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?.
The Journal of antimicrobial chemotherapy.
2017 09; 72(9):2407-2409. doi:
10.1093/jac/dkx176. [PMID: 28595364] - Paolo Maggi, Chiara Bellacosa, Armando Leone, Anna Volpe, Elena Delfina Ricci, Nicoletta Ladisa, Stefania Cicalini, Elisabetta Grilli, Rosaria Viglietti, Antonio Chirianni, Lara Ines Bellazzi, Renato Maserati, Canio Martinelli, Paola Corsi, Benedetto Maurizio Celesia, Federica Sozio, Gioacchino Angarano. Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Atherosclerosis.
2017 08; 263(?):398-404. doi:
10.1016/j.atherosclerosis.2017.05.004. [PMID: 28522147] - Amr Menshawy, Ammar Ismail, Abdelrahman Ibrahim Abushouk, Hussien Ahmed, Esraa Menshawy, Ahmed Elmaraezy, Mohamed Gadelkarim, Mohamed Abdel-Maboud, Attia Attia, Ahmed Negida. Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Archives of virology.
2017 Aug; 162(8):2181-2190. doi:
10.1007/s00705-017-3346-9. [PMID: 28361290] - Emilie R Elliot, Alieu Amara, Nicole Pagani, Laura Else, Graeme Moyle, Alex Schoolmeesters, Chris Higgs, Saye Khoo, Marta Boffito. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
The Journal of antimicrobial chemotherapy.
2017 07; 72(7):2035-2041. doi:
10.1093/jac/dkx108. [PMID: 28407075] - Francisco Antunes. Atazanavir sulfate + cobicistat for the treatment of HIV infection.
Expert review of anti-infective therapy.
2017 06; 15(6):569-576. doi:
10.1080/14787210.2017.1323634. [PMID: 28443391] - A Calcagno, N Pagani, A Ariaudo, G Arduino, C Carcieri, A D'Avolio, L Marinaro, M C Tettoni, L Trentini, G Di Perri, S Bonora. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
The Journal of antimicrobial chemotherapy.
2017 06; 72(6):1741-1744. doi:
10.1093/jac/dkx052. [PMID: 28333285] - David Metsu, Patrick Seraissol, Pierre Delobel, Christel Cinq-Frais, Lise Cuzin, Jacques Izopet, Etienne Chatelut, Peggy Gandia. Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?.
Fundamental & clinical pharmacology.
2017 Apr; 31(2):245-253. doi:
10.1111/fcp.12245. [PMID: 27664801] - Maria Concetta Postorino, Mattia Prosperi, Emanuele Focà, Eugenia Quiros-Roldan, Elisa Di Filippo, Franco Maggiolo, Alberto Borghetti, Nicoletta Ladisa, Massimo Di Pietro, Andrea Gori, Laura Sighinolfi, Angelo Pan, Nicola Mazzini, Carlo Torti. Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.
BMC infectious diseases.
2017 03; 17(1):212. doi:
10.1186/s12879-017-2322-z. [PMID: 28298195] - Divya Prakash Gnanadhas, Prasanta K Dash, Brady Sillman, Aditya N Bade, Zhiyi Lin, Diana L Palandri, Nagsen Gautam, Yazen Alnouti, Harris A Gelbard, JoEllyn McMillan, R Lee Mosley, Benson Edagwa, Howard E Gendelman, Santhi Gorantla. Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.
The Journal of clinical investigation.
2017 Mar; 127(3):857-873. doi:
10.1172/jci90025. [PMID: 28134625] - Jayanta Roy-Chowdhury, Namita Roy-Chowdhury, Irving Listowsky, Allan W Wolkoff. Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.
Clinical pharmacology in drug development.
2017 Mar; 6(2):140-146. doi:
10.1002/cpdd.314. [PMID: 28263463] - James Milburn, Rachael Jones, Jeremy B Levy. Renal effects of novel antiretroviral drugs.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2017 03; 32(3):434-439. doi:
10.1093/ndt/gfw064. [PMID: 27190354] - Sophie Jose, Mark Nelson, Andrew Phillips, David Chadwick, Roy Trevelion, Rachael Jones, Deborah I Williams, Lisa Hamzah, Caroline A Sabin, Frank A Post. Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
AIDS (London, England).
2017 02; 31(4):485-492. doi:
10.1097/qad.0000000000001353. [PMID: 28121667] - Andrea Vavassori, Paola Lanza, Ilaria Izzo, Salvatore Casari, Silvia Odolini, Serena Zaltron, Elena Festa, Francesco Castelli. [Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.].
Recenti progressi in medicina.
2017 Feb; 108(2):98-100. doi:
10.1701/2636.27101. [PMID: 28287204] - Frank A Post. Managing chronic kidney disease in the older adults living with HIV.
Current opinion in infectious diseases.
2017 02; 30(1):4-11. doi:
10.1097/qco.0000000000000333. [PMID: 27828808] - J B Dumond, J Chen, M Cottrell, C R Trezza, Hma Prince, C Sykes, C Torrice, N White, S Malone, R Wang, K B Patterson, N E Sharpless, A Forrest. Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.
CPT: pharmacometrics & systems pharmacology.
2017 02; 6(2):128-135. doi:
10.1002/psp4.12151. [PMID: 28032946] - Letizia Marinaro, Andrea Calcagno, Diego Ripamonti, Giovanni Cenderello, Veronica Pirriatore, Laura Trentini, Bernardino Salassa, Caterina Bramato, Giancarlo Orofino, Antonio D'Avolio, Marco Rizzi, Giovanni Di Perri, Stefano Rusconi, Stefano Bonora. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
2017 02; 87(?):30-36. doi:
10.1016/j.jcv.2016.11.015. [PMID: 27992788] - Dario Cattaneo, Davide Minisci, Valeria Cozzi, Agostino Riva, Paola Meraviglia, Emilio Clementi, Massimo Galli, Cristina Gervasoni. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?.
Antiviral therapy.
2017; 22(4):353-356. doi:
10.3851/imp3119. [PMID: 28008867] - Jenny Svärd, Sabina Mugusi, Doreen Mloka, Ujjwal Neogi, Genny Meini, Ferdinand Mugusi, Francesca Incardona, Maurizio Zazzi, Anders Sönnerborg. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
PloS one.
2017; 12(6):e0178942. doi:
10.1371/journal.pone.0178942. [PMID: 28582463] - Joshua A Beckman, Brian R Wood, Kevin L Ard, Christin N Price, Daniel A Solomon, Jonah P Zuflacht, Jessica Milian, Joshua C Prenner, Paul E Sax. Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.
PloS one.
2017; 12(10):e0181993. doi:
10.1371/journal.pone.0181993. [PMID: 29023508] - Marianne Harris, Bruce Ganase, Birgit Watson, Mark W Hull, Silvia A Guillemi, Wendy Zhang, Ramesh Saeedi, P Richard Harrigan. Efficacy and safety of 'unboosting' atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
HIV clinical trials.
2017 01; 18(1):39-47. doi:
10.1080/15284336.2016.1271503. [PMID: 28067119] - Sanelisiwe Nzuza, Sindiswa Zondi, Peter M O Owira. Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo.
PloS one.
2017; 12(11):e0183355. doi:
10.1371/journal.pone.0183355. [PMID: 29121676] - Theodoros Kelesidis, Thuy Tien T Tran, Todd T Brown, Carlee Moser, Heather J Ribaudo, Michael P Dube, Otto O Yang, Grace A McComsey, James H Stein, Judith S Currier. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Antiviral therapy.
2017; 22(2):113-126. doi:
10.3851/imp3093. [PMID: 27661466]